Log in

OTCMKTS:CRXMGene Biotherapeutics Stock Price, Forecast & News

$0.04
0.00 (0.00 %)
(As of 07/3/2020 11:41 AM ET)
Add
Compare
Today's Range
$0.03
Now: $0.04
$0.04
50-Day Range
$0.03
MA: $0.09
$0.15
52-Week Range
$0.02
Now: $0.04
$0.19
Volume20,843 shs
Average Volume93,138 shs
Market Capitalization$543,375.00
P/E RatioN/A
Dividend YieldN/A
Beta1.18
Taxus Cardium Pharmaceuticals Group, Inc. manages a portfolio of medical technologies in the United States. The company engages in the development and commercialization of Generx, an angiogenic gene therapy product candidate that is in Phase III clinical trial for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It also provides Excellagen technology platform, a FDA-approved flowable dermal matrix for advanced wound care treatment, as well as serves as a delivery platform for small molecule drugs, proteins, and biologics. In addition, the company develops a medical data analytics technology platform, which offers products for the life insurance and healthcare sectors. The company was formerly known as Cardium Therapeutics, Inc. and changed its name to Taxus Cardium Pharmaceuticals Group, Inc. in March 2014. Taxus Cardium Pharmaceuticals Group, Inc. was founded in 2003 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.68 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CRXM
CUSIPN/A
Phone858-436-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees6
Market Cap$543,375.00
Next Earnings DateN/A
OptionableNot Optionable

Receive CRXM News and Ratings via Email

Sign-up to receive the latest news and ratings for CRXM and its competitors with MarketBeat's FREE daily newsletter.

Gene Biotherapeutics (OTCMKTS:CRXM) Frequently Asked Questions

How has Gene Biotherapeutics' stock been impacted by COVID-19 (Coronavirus)?

Gene Biotherapeutics' stock was trading at $0.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRXM stock has decreased by 76.6% and is now trading at $0.0375. View which stocks have been most impacted by Coronavirus.

Has Gene Biotherapeutics been receiving favorable news coverage?

Media stories about CRXM stock have trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Gene Biotherapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Gene Biotherapeutics.

Who are some of Gene Biotherapeutics' key competitors?

Some companies that are related to Gene Biotherapeutics include Neuralstem (CUR), CytRx (CYTR), Innate Pharma (IPHA), Mymetics (MYMX) and Omni Bio Pharmaceutical (OMBP). View all competitors.

What other stocks do shareholders of Gene Biotherapeutics own?

Who are Gene Biotherapeutics' key executives?

Gene Biotherapeutics' management team includes the following people:
  • Mr. Christopher J. Reinhard, Co-Founder, Chairman, CEO, Pres & Treasurer (Age 65)
  • Mr. Jiayue Zhang, Exec. Chairman (Age 61)
  • Mr. Duane Linstrom, Gen. Counsel
  • Dr. Gabor M. Rubanyi, Chairman of Scientific Advisory Board & Chief Scientific Officer (Age 72)
  • Mr. Kelly D. Scott, VP of Bus. Devel. of Medtech Bus. Unit and EVP of Inner Cool Therapies Inc (Age 63)

What is Gene Biotherapeutics' stock symbol?

Gene Biotherapeutics trades on the OTCMKTS under the ticker symbol "CRXM."

How do I buy shares of Gene Biotherapeutics?

Shares of CRXM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gene Biotherapeutics' stock price today?

One share of CRXM stock can currently be purchased for approximately $0.04.

How big of a company is Gene Biotherapeutics?

Gene Biotherapeutics has a market capitalization of $543,375.00. Gene Biotherapeutics employs 6 workers across the globe.

What is Gene Biotherapeutics' official website?

The official website for Gene Biotherapeutics is www.cardiumthx.com.

How can I contact Gene Biotherapeutics?

Gene Biotherapeutics' mailing address is 11568 SORRENTO VALLEY ROAD SUITE 14, SAN DIEGO CA, 92121. The company can be reached via phone at 858-436-1000 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.